In human cancer samples, the up-regulated expression of ING5 was in gastric, breast, and colorectal cancers, but down-regulated in head and neck squamous cell carcinoma (HNSCC), lung cancer, osteosarcoma, prostate cancer, ovarian cancer, hepatocellular carcinoma (HCC), esophageal cancer, and thyroid cancer. Here, ING5 is linked to prostate cancer.